Canaccord raised the firm’s price target on Palvella Therapeutics (PVLA) to $66 from $52 and keeps a Buy rating on the shares. The firm said its 2Q25 earnings report was incremental following enrollment completion of its phase 3 SELVA trial for mLM, which exceeded its target (n=40) by over 25% (n=51). Top-line results are on track for 1Q26.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics price target raised to $75 from $38 at H.C. Wainwright
- Palvella Therapeutics Advances Rare Disease Pipeline
- Palvella Therapeutics price target raised to $60 from $50 at Chardan
- Palvella Therapeutics: Strong Financial Position and Clinical Progress Justify Buy Rating with Raised Price Target
- Positive Buy Rating for Palvella Therapeutics Driven by Promising Phase 3 Trial Developments and Market Potential